Australian biotech firm Heidi joins overseas peers in setting up Hong Kong base
Australian healthcare start-up Heidi plans to open its first North Asia office in Hong Kong this year, aiming to tap opportunities created by the city’s acute doctor shortage and ageing population through its proprietary artificial intelligence platform. Heidi co-founder and CEO Thomas Kelly said Hong Kong would serve as “an important market for us to…
Australian healthcare start-up Heidi plans to open its first North Asia office in Hong Kong this year, aiming to tap opportunities created by the city’s acute doctor shortage and ageing population through its proprietary artificial intelligence platform.
Heidi co-founder and CEO Thomas Kelly said Hong Kong would serve as “an important market for us to unlock North Asia”.
“We think of China more broadly, but also surrounding countries in the region,” he said. “It will be one of our main areas of investment.”
Kelly, a former doctor, said the city’s advanced healthcare and tech ecosystem, strong academic base and openness to AI innovation made it an ideal launchpad for the company’s next phase of growth.
The Melbourne-based firm is still in talks with “a number of different venues” for its Hong Kong office. Heidi raised US$65 million in a Series B funding round in early October, valuing the company at US$465 million.
